Skip to main content

Table 1 Baseline characteristics of enrolled population

From: Association between the triglyceride glucose index and coronary collateralization in coronary artery disease patients with chronic total occlusion lesions

 

Total populations

Rentrop Classification (0-1)

Rentrop Classification

(2-3)

P

(n=1093)

(n=318)

(n=775)

Demographic data

    

Age (years)

58.76±10.17

58.0±10.11

59.1±10.19

0.064

Male sex, n (%)

936 (85.6 %)

270 (85 %)

666 (86 %)

0.659

BMI (Kg/m²)

26.4±3.30

26.7±3.21

26.2±3.32

0.019*

SBP (mmHg)

130.1±16.49

129.7±15.63

130.3±16.84

0.721

DBP (mmHg)

77.1±11.22

77.3±10.54

77.0±11.49

0.856

Current Smokers, n (%)

597 (55 %)

188 (59 %)

409 (53 %)

0.056

Medical history

    

HTN, n (%)

734 (67 %)

206 (65 %)

528 (68 %)

0.284

T2DM, n (%)

463 (42 %)

147 (46 %)

316 (41 %)

0.098

MetS, n (%)

    

Hypertriglyceridemia, n (%)

446 (41 %)

202 (64 %)

244 (32 %)

<0.001*

Hypercholesterolemia, n (%)

613 (56 %)

199 (63 %)

414 (53 %)

0.002*

Previous MI, n (%)

179 (16 %)

129 (17 %)

50 (16 %)

0.708

Previous Stroke, n (%)

109 (10 %)

39 (12 %)

70 (9 %)

0.105

Number of components of Mets

    

0

36 (3 %)

6 (2 %)

30 (4 %)

0.095

1

142 (13 %)

26 (8 %)

116 (15 %)

0.002*

2

274 (25 %)

59 (19 %)

215 (28 %)

0.001*

3

296 (27 %)

95 (30 %)

201 (26 %)

0.183

4

240 (21 %)

85 (27 %)

155 (20 %)

0.015*

5

105 (10 %)

47 (15 %)

58 (7 %)

<0.001*

Laboratory measurement

    

MONO, 1012/L

0.41±0.14

0.43±0.14

0.40±0.14

0.002*

eGFR

91.4±16.89

91.2±18.15

91.4±16.36

0.693

CREA, mmol/L

78.3±19.61

79.2±21.28

78.0±18.89

0.636

UREA, mmol/L

5.6±1.83

5.8±1.90

5.5±1.80

0.092

UA, mmol/L

355.4±94.97

369.8±97.57

349.6±93.32

<0.001

FBG, mmol/L

5.88 (5.11-7.25)

6.23 (5.22-8.10)

5.75 (5.06-7.00)

<0.001*

GA, %

14.4 (13.0-17.2)

14.5 (12.9-18.0)

14.4 (13.0-16.8)

0.455

HbA1C, %

6.1 (5.7-6.9)

6.2 (5.8-7.4)

6.1 (5.7-6.8)

0.001*

TyG index

9.3±0.65

9.3±0.65

8.8±0.53

<0.001

TC, mmol/L

3.9±0.99

4.1±1.07

3.8±0.94

<0.001

TG, mmol/L

1.7±0.91

2.2±1.11

1.6±0.73

<0.001

HDL-C, mmol/L

1.0±0.25

1.0±0.24

1.1±0.25

<0.001*

LDL-C, mmol/L

2.3±0.88

2.4±0.95

2.2±0.85

0.005*

Non-HDL-C, mmol/L

2.9±0.97

3.1±1.05

2.8±0.91

<0.001*

Hs CRP, mg/L

1.02 (0.52-2.64)

1.13 (0.68-3.16)

0.97 (0.48-2.38)

0.002*

LVEF, %

59.3±8.59

59.0±8.91

59.5±8.46

0.343

Cardiovascular Medication

    

Antiplatelet therapy, n (%)

940 (86 %)

274 (86 %)

666 (86 %)

0.921

β-blockers, n (%)

660 (60 %)

200 (63 %)

460 (59 %)

0.277

ACEI/ARB, n (%)

360 (33 %)

112 (35 %)

248 (32 %)

0.304

Statins, n (%)

902 (83 %)

267 (84 %)

635 (82 %)

0.423

CCB, n (%)

305 (28 %)

80 (25 %)

225 (29 %)

0.195

Severity of CAD

   

0.912

One-vessel disease, n (%)

154 (14 %)

43 (14 %)

111 (14 %)

0.775

Two-vessel disease, n (%)

313 (29 %)

90 (28 %)

223 (29 %)

0.941

Three-vessel disease, n (%)

626 (57 %)

185 (58 %)

441 (57 %)

0.737

CTO related artery

   

0.078

RCA

528 (48 %)

139 (44 %)

389 (50 %)

0.054

LCX

192 (18 %)

55 (17 %)

137 (18 %)

0.93

LAD

373 (34 %)

124 (39 %)

249 (32 %)

0.035*

Grade of collaterals

    

0

69 (6 %)

69 (22 %)

-

 

1

249 (23 %)

249 (78 %)

-

 

2

551 (50 %)

-

551 (71 %)

 

3

224 (21 %)

-

224 (29 %)

 

ISR-CTO

104 (10 %)

37 (12 %)

67 (9 %)

0.14

  1. * Indicates the difference between two groups was statistically significant
  2. Abbreviations: BMI Body mass index, SBP Systolic blood pressure, DBP Diastolic blood pressure, HTN Hypertension, T2DM Type2 diabetes mellitus, PCI Percutaneous coronary intervention, MetS Metabolic syndrome, MI Myocardial infarction, MONO Monocyte count, eGFR Estimated glomerular filtration rate, CREA Creatinine, UREA Urea, UA Uric acid, FPG Fasting plasma glucose, GA Glycated albumin, HbA1c Glycosylated hemoglobin A1c, TyG index Triglyceride glucose index, TC Total cholesterol, TG Triglyceride, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, non HDL-C Non high-density lipoprotein cholesterol, hs-CRP High-sensitivity C-reactive protein, LVEF Left ventricular ejection fraction, ACEI/ARB Angiotensin-converting enzyme inhibitors / angiotensin receptor blockers, CCB Calcium channel blocker, CAD Coronary artery disease, CTO Chronic total lesion, RCA Right coronary artery, LCX Left circumflex coronary artery, LAD Left anterior descending artery, ISR In-stent restenosis
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X